Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Summary

The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment phase.

Timeline

Start

2010-09

Primary completion

2012-04

Completion

2012-04

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Esl 800 mg Once Daily (QD) vs Placebo; p = 0.9321; Dunnett's test NCT01124097 ↗

registry analysis (superiority or other test); Esl 1200 mg QD vs Placebo; p = 0.2610; Dunnett's test NCT01124097 ↗

registry analysis (superiority or other test); Esl 1600 mg QD vs Placebo; p = 0.4764; Dunnett's test NCT01124097 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eslicarbazepine acetate	Unknown	800 mg	—
Subject	Eslicarbazepine acetate	Unknown	1200 mg	—
Subject	Eslicarbazepine acetate	Unknown	1600 mg	—

Indications